Zobrazeno 1 - 10
of 5 685
pro vyhledávání: '"cancer cachexia"'
Autor:
Satomi Okamura, Koji Amano, Saori Koshimoto, Sayaka Arakawa, Hiroto Ishiki, Eriko Satomi, Tatsuya Morita, Takashi Takeuchi, Naoharu Mori, Tomomi Yamada
Publikováno v:
Current Oncology, Vol 31, Iss 10, Pp 6133-6143 (2024)
Pharmacists’ roles in cachexia care are unclear. This study aimed to clarify the knowledge and practice of cachexia care and identify factors related to the practice of cachexia care among pharmacists. Information on the knowledge and practice of c
Externí odkaz:
https://doaj.org/article/8c44b0b1e2194cc1b67fc188bb50a3fe
Autor:
Yating Qin, Hailun Xie, Tong Liu, Heyang Zhang, Chenan Liu, Xiangrui Li, Zhaoting Bu, Xiaoyue Liu, Shiqi Lin, Yue Chen, Xin Zheng, Hong Zhao, Jinyu Shi, Hanping Shi
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract Studies have shown that the cachexia index (CXI) is a useful predictor of cachexia in patients with colorectal cancer. However, the application of the CXI is limited stemming from the intricacy and additional cost of radiographic examination
Externí odkaz:
https://doaj.org/article/71570413fce14be7bc76ab7a91a9084e
Autor:
Hailun Xie, Lishuang Wei, Guotian Ruan, Heyang Zhang, Jinyu Shi, Shiqi Lin, Chenan Liu, Xiaoyue Liu, Xin Zheng, Yue Chen, Junqiang Chen, Hanping Shi
Publikováno v:
Journal of Cachexia, Sarcopenia and Muscle, Vol 15, Iss 5, Pp 2084-2093 (2024)
Abstract Background The Asian Working Group for Cachexia (AWGC) proposed the first consensus report on diagnostic criteria for cachexia in Asians in 2023. However, the current consensus lacks cohort evidence to validate its effectiveness and practica
Externí odkaz:
https://doaj.org/article/37be02198cfd43f7963f3e4f65e9df4b
Autor:
Zongliang Lu, Li Wang, Zhenyu Huo, Na Li, Ning Tong, Feifei Chong, Jie Liu, Yaowen Zhang, Hongxia Xu
Publikováno v:
Journal of Cachexia, Sarcopenia and Muscle, Vol 15, Iss 5, Pp 1953-1964 (2024)
Abstract Background Cancer cachexia‐induced skeletal muscle fibrosis (SMF) impairs muscle regeneration, alters the muscle structure and function, reduces the efficacy of anticancer drugs, diminishes the patient's quality of life and shortens overal
Externí odkaz:
https://doaj.org/article/426c52c8327843b49336e4958d42f40b
Autor:
Samet Agca, Aylin Domaniku‐Waraich, Sevval Nur Bilgic, Melis Sucuoglu, Meric Dag, Sukru Anil Dogan, Serkan Kir
Publikováno v:
Journal of Cachexia, Sarcopenia and Muscle, Vol 15, Iss 5, Pp 1898-1914 (2024)
Abstract Background Tumour‐induced skeletal muscle wasting in the context of cancer cachexia is a condition with profound implications for patient survival. The loss of muscle mass is a significant clinical obstacle and is linked to reduced toleran
Externí odkaz:
https://doaj.org/article/d0200d5c1178411a990b0436bd6dd43a
Autor:
Isaias Gutierrez-Leal, Diana Caballero-Hernández, Alonso A. Orozco-Flores, Ricardo Gomez-Flores, Deyanira Quistián-Martínez, Patricia Tamez-Guerra, Reyes Tamez-Guerra, Cristina Rodríguez-Padilla
Publikováno v:
BMC Neuroscience, Vol 25, Iss 1, Pp 1-9 (2024)
Abstract Background Adipose and muscle tissue wasting outlines the cachectic process during tumor progression. The sympathetic nervous system (SNS) is known to promote tumor progression and research suggests that it might also contribute to cancer-as
Externí odkaz:
https://doaj.org/article/9574ae6b5f3f482aa85241091153997a
Autor:
Min Deng, Jianhua Cao, Gregory van derKroft, David P.J. vanDijk, Merel R. Aberle, Andrej Grgic, Ulf P. Neumann, Georg Wiltberger, Benjamin Balluff, Frank G. Schaap, Ron M.A. Heeren, Steven W.M. Olde Damink, Sander S. Rensen
Publikováno v:
Journal of Cachexia, Sarcopenia and Muscle, Vol 15, Iss 4, Pp 1283-1297 (2024)
Abstract Background Cancer cachexia is a multifactorial metabolic syndrome characterized by systemic inflammation and ongoing skeletal muscle loss resulting in weakness, poor quality of life, and decreased survival. Whereas lipid accumulation in skel
Externí odkaz:
https://doaj.org/article/a21945d9b4a94f918dbf70a8e0d468eb
Autor:
Hironori Fujii, Akitaka Makiyama, Kayoko Nishimura, Hirotoshi Iihara, Chiemi Hirose, Koichi Ohata, Yunami Yamada, Daichi Watanabe, Itaru Yasufuku, Naoki Okumura, Yoshihiro Tanaka, Takao Takahashi, Ryo Kobayashi, Nobuhisa Matsuhashi, Akio Suzuki
Publikováno v:
Journal of Pharmaceutical Health Care and Sciences, Vol 10, Iss 1, Pp 1-9 (2024)
Abstract Background Anamorelin is expected to improve cancer cachexia by increasing lean body mass (LBM) due to increased appetite and protein synthesis. However, the effect of anamorelin on cancer cachexia in real-world practice is unclear. The purp
Externí odkaz:
https://doaj.org/article/ee8816608d5f438b928ba67da044ed10
Publikováno v:
Journal of Cachexia, Sarcopenia and Muscle, Vol 15, Iss 3, Pp 781-793 (2024)
Abstract Cancer cachexia (CC) is a devastating metabolic syndrome characterized by skeletal muscle wasting and body weight loss, posing a significant burden on the health and survival of cancer patients. Despite ongoing efforts, effective treatments
Externí odkaz:
https://doaj.org/article/47f3e69627d340a58031be6152ac5d78
Autor:
Leo R. Brown, Mariana S. Sousa, Michael S. Yule, Vickie E. Baracos, Donald C. McMillan, Jann Arends, Trude R. Balstad, Asta Bye, Olav Dajani, Ross D. Dolan, Marie T. Fallon, Christine Greil, Marianne J. Hjermstad, Gunnhild Jakobsen, Matthew Maddocks, James McDonald, Inger O. Ottestad, Iain Phillips, Judith Sayers, Melanie R. Simpson, Ola M. Vagnildhaug, Tora S. Solheim, Barry J.A. Laird, Richard J.E. Skipworth, the Cancer Cachexia Endpoints Working Group
Publikováno v:
Journal of Cachexia, Sarcopenia and Muscle, Vol 15, Iss 3, Pp 816-852 (2024)
Abstract Significant variation exists in the outcomes used in cancer cachexia trials, including measures of body composition, which are often selected as primary or secondary endpoints. To date, there has been no review of the most commonly selected
Externí odkaz:
https://doaj.org/article/97fbbcfba63e4845963cae99e9a6f886